Binding proteins specific for insulin-like growth factors and uses thereof

Patent metadata

Field	Value
Publication number	US-9181336-B2
Application number	US-201313803711-A
Country	US
Kind code	B2
Filing date	Mar 14, 2013
Priority date	Dec 13, 2005
Publication date	Nov 10, 2015
Grant date	Nov 10, 2015

Abstract

Binding proteins, such as antibodies directed to IGF-II with cross-reactivity to IGF-I and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the IGF-II with cross-reactivity to IGF-I are disclosed. Also discussed are nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3.

First claim

What is claimed is:

1. An isolated antibody or antibody fragment thereof, wherein said antibody or antibody fragment thereof comprises:
a heavy chain complementarity determining region 1 (hCDR 1) having the amino acid sequence set forth in SEQ ID NO: 21 (Ser Tyr Tyr Trp Ser);
a heavy chain complementarity determining region 2 (hCDR2) having the amino acid sequence set forth in SEQ ID NO: 22 (Tyr Phe Phe Tyr Ser Gly Thr Asn Tyr Asn Pro Ser Leu Lys Ser);
a heavy chain complementarity determining region 3 (hCDR3) having the amino acid sequence set forth in SEQ ID NO: 23 (Ile Thr Gly Thr Thr Lys Gly Gly Met Asp Val);
a light chain complementarity determining region 1 (1CDR1) having the amino acid sequence set forth in SEQ ID NO: 30 (Thr Gly Arg Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His);
a light chain complementarity determining region 2(1CDR2) having the amino acid sequence set forth in SEQ ID NO: 31 (Gly Asn Ser Asn Arg Pro Ser); and
a light chain complementarity determining region 3 (1CDR3) having the amino acid sequence set forth in SEQ ID NO: 32 (Gin Ser Tyr Asp Ser Ser Leu Ser Gly Ser Val).

2. The antibody or antibody fragment thereof of claim 1 , wherein the antibody or antibody fragment comprises a heavy chain polypeptide having the sequence set forth in SEQ ID NO: 10; or wherein the antibody comprises a light chain polypeptide having the sequence set forth in SEQ ID NO: 12.

3. The antibody or antibody fragment thereof of claim 1 , wherein the antibody or antibody fragment comprises a heavy chain polypeptide having the sequence set forth in SEQ ID NO: 10; and wherein the antibody comprises a light chain polypeptide having the sequence set forth in SEQ ID NO: 12.

4. The antibody or antibody fragment thereof of claim 1 , wherein the antibody is a monoclonal antibody.

5. The antibody or antibody fragment thereof of claim 4 , wherein said antibody is a fully human monoclonal antibody.

6. The human monoclonal antibody of claim 5 , wherein said antibody does not bind specifically to Insulin Growth Factor II (IGF-II) or Insulin Growth Factor I (IGF-I) protein when said protein is bound to Insulin Growth Factor Binding Protein (IGFBP).

7. The antibody or antibody fragment thereof of claim 5 , wherein said antibody fragment is selected from the group consisting of Fab, Fab′, F(ab′)2 and Fv.

8. The antibody or antibody fragment thereof of claim 1 , wherein said antibody is monoclonal antibody 7.34.1 (ATCC Accession Number PTA-7423).

9. The antibody or antibody fragment thereof of claim 1 in a mixture with a pharmaceutically acceptable carrier.

10. A conjugate comprising the antibody or antibody fragment thereof of claim 5 and a therapeutic agent.

11. The conjugate of claim 10 , wherein the therapeutic agent is a toxin.

12. The conjugate of claim 10 , wherein the therapeutic agent is a radioisotope.

Assignees

• Medimmune Ltd

Inventors

• Raeber Olivia
• Gazit-Bornstein Gadi
• Yang Xiao-Dong
• Cartlidge Susan Ann
• Tonge David William

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P19/10

  for osteoporosis · CPC title

• C07K2317/56

  variable (Fv) region, i.e. VH and/or VL · CPC title